Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 1:28 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | T. Rowe Price Investment Management Inc. | 10,734,389 19.000% | 74,659 (+0.70%) | View |
| 2024-11-14 12:02 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | Vestal Point Capital LP | 5,028,500 8.900% | 5,028,500 (New Position) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 3,497,766 6.200% | 0 (Unchanged) | View |
| 2024-10-24 2:02 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 3,497,766 6.200% | 2,225,654 (+174.96%) | View |
| 2024-08-08 4:48 pm Unchanged | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 4,328,883 7.700% | 0 (Unchanged) | View |
| 2024-07-10 2:17 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | T. Rowe Price Investment Management Inc. | 10,659,730 18.900% | 3,983,974 (+59.68%) | View |
| 2024-05-13 7:09 pm Purchase | 13D | Black Diamond Therapeutics, Inc. BDTX | Stephanie Brecher | 4,546,947 8.100% | 1,098,190 (+31.84%) | View |
| 2024-05-09 8:48 pm Purchase | 13D | Black Diamond Therapeutics, Inc. BDTX | RA CAPITAL MANAGEMENT L.P. | 2,788,028 4.950% | 198,124 (+7.65%) | View |
| 2024-03-11 1:14 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | T. Rowe Price Investment Management Inc. | 6,675,756 12.900% | 2,747,877 (+69.96%) | View |
| 2024-02-14 10:04 am Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | T. Rowe Price Investment Management Inc. | 3,927,879 7.600% | 3,927,879 (New Position) | View |
| 2024-02-13 06:05 am Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 8,517,839 16.500% | 3,140,000 (+58.39%) | View |
| 2023-11-09 5:24 pm Unchanged | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 4,328,883 8.400% | 0 (Unchanged) | View |
| 2023-02-14 4:14 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 5,377,839 14.800% | 1,389,437 (+34.84%) | View |
| 2022-07-08 4:57 pm Sale | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 1,272,112 3.500% | -976,355 (-43.42%) | View |
| 2022-04-14 12:01 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 3,988,402 11.000% | 548,402 (+15.94%) | View |
| 2022-02-11 4:57 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 3,440,000 9.500% | 1,540,000 (+81.05%) | View |
| 2022-02-09 3:33 pm Sale | 13G | Black Diamond Therapeutics, Inc. BDTX | The Vanguard Group - 23-1945930 | 1,014,791 2.800% | -831,171 (-45.03%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 2,248,467 6.200% | 2,248,467 (New Position) | View |
| 2021-02-11 4:58 pm Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 1,900,000 5.300% | 1,900,000 (New Position) | View |
| 2021-02-10 10:39 am Purchase | 13G | Black Diamond Therapeutics, Inc. BDTX | The Vanguard Group - 23-1945930 | 1,845,962 5.130% | 1,845,962 (New Position) | View |